Oryzon Genomics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Oryzon Genomics kazanç ve gelirin sırasıyla yıllık 76% ve 61.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 73.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -3.5% olacağı tahmin edilmektedir.

Anahtar bilgiler

76.0%

Kazanç büyüme oranı

73.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	37.1%
Gelir büyüme oranı	61.7%
Gelecekteki özkaynak getirisi	-3.5%
Analist kapsamı	Low
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

LSE:0RDB - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	6	-9	-19	N/A	3
12/31/2025	14	-6	-16	N/A	4
12/31/2024	4	-4	-13	N/A	4
9/30/2024	16	-5	N/A	N/A	N/A
6/30/2024	12	-4	-14	-2	N/A
3/31/2024	15	-3	N/A	N/A	N/A
12/31/2023	16	-4	-17	-1	N/A
9/30/2023	17	-4	N/A	N/A	N/A
6/30/2023	17	-4	-21	-3	N/A
3/31/2023	17	-5	N/A	N/A	N/A
12/31/2022	17	-5	-17	-2	N/A
9/30/2022	10	-3	N/A	N/A	N/A
6/30/2022	14	-5	-15	-3	N/A
3/31/2022	12	-5	N/A	N/A	N/A
12/31/2021	12	-5	-18	-4	N/A
9/30/2021	11	-4	N/A	N/A	N/A
6/30/2021	10	-4	-17	-4	N/A
3/31/2021	7	-5	N/A	N/A	N/A
12/31/2020	12	-4	-17	-6	N/A
9/30/2020	12	-4	N/A	N/A	N/A
6/30/2020	13	-4	-16	-4	N/A
3/31/2020	13	-4	N/A	N/A	N/A
12/31/2019	12	-4	-15	-4	N/A
9/30/2019	10	-4	N/A	N/A	N/A
6/30/2019	9	-4	-11	-3	N/A
3/31/2019	8	-2	N/A	N/A	N/A
12/31/2018	8	-1	-9	-1	N/A
9/30/2018	7	-2	N/A	N/A	N/A
6/30/2018	6	-2	N/A	-5	N/A
3/31/2018	6	-6	N/A	N/A	N/A
12/31/2017	5	-6	N/A	-6	N/A
9/30/2017	6	-6	N/A	N/A	N/A
6/30/2017	6	-6	N/A	-4	N/A
3/31/2017	5	-6	N/A	N/A	N/A
12/31/2016	5	-6	N/A	-5	N/A
9/30/2016	6	-5	N/A	N/A	N/A
6/30/2016	6	-4	N/A	-1	N/A
3/31/2016	8	-1	N/A	N/A	N/A
12/31/2015	8	-1	N/A	1	N/A
9/30/2015	8	-1	N/A	N/A	N/A
6/30/2015	7	-1	N/A	N/A	N/A
3/31/2015	11	2	N/A	N/A	N/A
12/31/2014	19	8	N/A	15	N/A
12/31/2013	3	-3	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 0RDB önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.1% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: 0RDB önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: 0RDB önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: 0RDB şirketinin gelirinin (yıllık 61.7% ) UK pazarından (yıllık 3.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 0RDB şirketinin gelirinin (yıllık 61.7% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 0RDB 3 yıl içinde kârsız olması bekleniyor.

Oryzon Genomics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast breakeven date moved forward to 2025

Recent updates

New minor risk - Market cap size

Forecast to breakeven in 2025

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

No longer forecast to breakeven

Oryzon Genomics, S.A. Announces Presentation of Final Data from Portico, Vafidemstat's Global Phase IIb Trial in Borderline Personal Disorder, at the 37th ECNP Annual Conference

Oryzon Genomics S.A. Presents Preliminary Data from Ongoing Phase Ib Frida Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory Flt3-Mut Aml Patients At Eha-2024

Forecast breakeven date moved forward to 2025

Oryzon Genomics, S.A. Secures Another Important Patent for its Lead CNS Asset, Vafidemstat

Forecast breakeven date pushed back to 2026

New minor risk - Share price stability

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

New major risk - Revenue and earnings growth

New minor risk - Profitability

Forecast to breakeven in 2025

Oryzon Genomics, S.A. Announces Topline Results from Phase IIb Portico Study of Vafidemstat in Borderline Personality Disorder

New major risk - Financial position

Oryzon Genomics S.A. announced that it expects to receive €45 million in funding from Nice & Green SA

Oryzon Genomics, S.A. Announces Last Patient Last Visit in Its Phase IIb Portico Study for Borderline Personality Disorder

Oryzon Genomics, S.A. Presents Blinded Aggregated Safety Data from Vafidemstat's Ongoing Phase IIB Portico Trial in Borderline Personal Disorder

New major risk - Financial position

Oryzon Genomics, S.A. Reports New Preliminary Blinded Aggregate Safety Data from Its Ongoing Phase IIb Portico Trial

Oryzon Genomics, S.A. Presents Positive Preclinical Data of Ory-4001 for the Treatment of Charcot-Marie-Tooth Disease Presented At the 2023 Peripheral Nerve Society Annual Meeting

Insufficient new directors

Oryzon Genomics, S.A. to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease At the 2023 Peripheral Nerve Society Annual Meeting

Forecast to breakeven in 2025

Oryzon Genomics S.A. announced that it has received €1.800407 million in funding

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

Oryzon Genomics S.A. announced that it expects to receive €20 million in funding from Nice & Green SA

Oryzon Genomics S.A. At Eha-2022: Iadademstat 42-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

Oryzon Genomics S.A. Announces Appointment of Douglas V. Faller as Global Chief Medical Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

Oryzon Genomics S.A. Presents Iadademstat 36-Month Alice Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Oryzon Announces $1 Million Grant from Kabuki Syndrome Philanthropists to Support A Precision Medicine Phase I/Ii Trial with Vafidemstat

First half 2021 earnings released: €0.019 loss per share (vs €0.026 loss in 1H 2020)

Oryzon Genomics S.A. Receives Approval to Start EVOLUTION Phase IIb trial with vafidemstat in schizophrenia

Oryzon Genomics, S.A. Announces FDA Approval of IND for Portico, Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML

ORYZON to Present New Clinical Data

Oryzon Genomics, S.A. Announces Successful pre-IND Meeting with FDA for the Clinical Development of vafidemstatin Borderline Personality Disorder

Oryzon Genomics S.A. Presents Vafidemstat 12-Month Clinical Data from Its Phase IIa Clinical Trials

Full year 2020 earnings released

New 90-day high: €3.84

Oryzon Genomics S.A. Launches Pioneering Schizophrenia Precision Medicine Study in Collaboration with Columbia Psychiatry

New 90-day high: €3.18

New 90-day low: €2.69

Oryzon Genomics S.A. to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

Oryzon Genomics, S.A. Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

Oryzon Genomics S.A. Announces Executive Changes

Third quarter earnings released

New 90-day low: €2.71

Oryzon Genomics S.A. has completed a Follow-on Equity Offering in the amount of €20.00075 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin